Trending Stock News

RingCentral, Inc. (RNG) Forms $67.10 Double Top; Onconova Therapeutics (ONTX) SI Increased By 55.34%

RingCentral, Inc. (NYSE:RNG) Logo

Onconova Therapeutics Inc (NASDAQ:ONTX) had an increase of 55.34% in short interest. ONTX’s SI was 838,200 shares in April as released by FINRA. Its up 55.34% from 539,600 shares previously. With 652,100 avg volume, 1 days are for Onconova Therapeutics Inc (NASDAQ:ONTX)’s short sellers to cover ONTX’s short positions. The SI to Onconova Therapeutics Inc’s float is 13.63%. The stock decreased 3.46% or $0.0201 during the last trading session, reaching $0.56. About 421,150 shares traded. Onconova Therapeutics, Inc. (NASDAQ:ONTX) has declined 70.37% since April 22, 2017 and is downtrending. It has underperformed by 81.92% the S&P500.

RingCentral, Inc. (RNG) formed double top with $69.11 target or 3.00% above today’s $67.10 share price. RingCentral, Inc. (RNG) has $5.28 billion valuation. The stock decreased 1.18% or $0.8 during the last trading session, reaching $67.1. About 541,675 shares traded. RingCentral, Inc. (NYSE:RNG) has risen 143.04% since April 22, 2017 and is uptrending. It has outperformed by 131.49% the S&P500.

Onconova Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule drug candidates to treat cancer. The company has market cap of $10.61 million. The companyÂ’s clinical-stage product candidates include Rigosertib IV, which is in Phase III clinical trials for patients with higher risk myelodysplastic syndromes ; Rigosertib oral in combination with azacitidine that is in Phase II clinical trials for patients with MDS and acute myelogenous leukemia; and Rigosertib oral, which is in Phase II clinical trials for patients with lower risk MDS. It currently has negative earnings. The Company’s clinical-stage product candidates also comprise Briciclib, which is in Phase I multisite dose-escalation trial for patients with advanced solid tumors; and Recilisib that has completed four Phase I clinical trials for patients with acute radiation syndromes.

Among 2 analysts covering Onconova Therapeutics (NASDAQ:ONTX), 1 have Buy rating, 0 Sell and 1 Hold. Therefore 50% are positive. Onconova Therapeutics had 14 analyst reports since September 3, 2015 according to SRatingsIntel. H.C. Wainwright maintained Onconova Therapeutics, Inc. (NASDAQ:ONTX) rating on Thursday, January 4. H.C. Wainwright has “Buy” rating and $6.0 target. The firm has “Buy” rating by H.C. Wainwright given on Thursday, January 18. The stock has “Buy” rating by H.C. Wainwright on Friday, March 9. The stock of Onconova Therapeutics, Inc. (NASDAQ:ONTX) earned “Hold” rating by Maxim Group on Wednesday, January 17. Maxim Group maintained the stock with “Buy” rating in Tuesday, August 15 report. The stock has “Buy” rating by H.C. Wainwright on Thursday, November 9. The rating was maintained by Maxim Group with “Buy” on Tuesday, June 6. On Monday, March 26 the stock rating was maintained by H.C. Wainwright with “Buy”. As per Monday, October 9, the company rating was initiated by H.C. Wainwright. H.C. Wainwright maintained Onconova Therapeutics, Inc. (NASDAQ:ONTX) rating on Tuesday, December 12. H.C. Wainwright has “Buy” rating and $6.0 target.

Since December 11, 2017, it had 0 buys, and 19 insider sales for $13.15 million activity. Shmunis Vladimir had sold 48,666 shares worth $2.29M. $187,560 worth of RingCentral, Inc. (NYSE:RNG) was sold by Dhruv Mitesh. $643,420 worth of stock was sold by Shah Praful on Tuesday, February 20. On Wednesday, January 10 the insider Sipes David sold $454,398. Marlow John H sold $803,642 worth of stock or 12,639 shares.

Investors sentiment decreased to 0.97 in Q4 2017. Its down 0.02, from 0.99 in 2017Q3. It dropped, as 10 investors sold RingCentral, Inc. shares while 76 reduced holdings. 35 funds opened positions while 48 raised stakes. 56.14 million shares or 1.08% more from 55.54 million shares in 2017Q3 were reported. Fmr Ltd Liability Co accumulated 6.40M shares. Bailard owns 47,700 shares or 0.15% of their US portfolio. Wellington Mngmt Group Inc Llp stated it has 0% of its portfolio in RingCentral, Inc. (NYSE:RNG). Gradient Investments Ltd owns 299 shares. Wells Fargo And Mn has 513,255 shares for 0.01% of their portfolio. Parametrica holds 0.13% or 4,166 shares in its portfolio. Hbk Invs Limited Partnership invested in 34,700 shares or 0.02% of the stock. California State Teachers Retirement Systems owns 0.01% invested in RingCentral, Inc. (NYSE:RNG) for 102,571 shares. Blair William & Il stated it has 0% in RingCentral, Inc. (NYSE:RNG). Soros Fund Mgmt Limited Com, New York-based fund reported 250,000 shares. Geode Capital Mgmt Lc has invested 0.01% in RingCentral, Inc. (NYSE:RNG). Hanseatic Mgmt Service Inc invested 0% of its portfolio in RingCentral, Inc. (NYSE:RNG). Barclays Public Ltd Llc holds 0% or 94,731 shares. Swiss National Bank & Trust has 0.01% invested in RingCentral, Inc. (NYSE:RNG). Voloridge Management Lc reported 19,366 shares stake.

Among 18 analysts covering RingCentral (NYSE:RNG), 15 have Buy rating, 0 Sell and 3 Hold. Therefore 83% are positive. RingCentral had 61 analyst reports since July 21, 2015 according to SRatingsIntel. The stock has “Buy” rating by Jefferies on Wednesday, August 2. Northland Capital maintained the shares of RNG in report on Thursday, July 20 with “Buy” rating. The company was maintained on Monday, February 12 by Jefferies. William Blair maintained the stock with “Buy” rating in Monday, February 12 report. The stock has “Buy” rating by Dougherty & Company on Wednesday, April 26. Jefferies maintained it with “Buy” rating and $52.0 target in Thursday, November 9 report. On Friday, August 26 the stock rating was initiated by Robert W. Baird with “Neutral”. Bank of America maintained RingCentral, Inc. (NYSE:RNG) rating on Wednesday, October 25. Bank of America has “Buy” rating and $50 target. The rating was maintained by SunTrust with “Buy” on Monday, February 12. The rating was maintained by Northland Capital with “Buy” on Thursday, August 3.

Analysts await RingCentral, Inc. (NYSE:RNG) to report earnings on April, 24. They expect $-0.06 earnings per share, up 33.33% or $0.03 from last year’s $-0.09 per share. After $-0.08 actual earnings per share reported by RingCentral, Inc. for the previous quarter, Wall Street now forecasts -25.00% EPS growth.

RingCentral, Inc. (NYSE:RNG) Institutional Positions Chart

Leave a Reply

Your email address will not be published. Required fields are marked *